MedTrace Logo

SPIRIT Small Vessel Registry

NCT00783796 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-05-08

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and effectiveness of the 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two de novo native coronary artery lesions in small vessels, each in a different epicardial vessel.

Conditions

Interventions

DEVICE

2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System

Treatment of a maximum of two de novo native coronary artery lesions in small vessels.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Marco A. Costa, MD, PhD · Case Western University Hospital, Cleveland, OH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-10-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00783796 on ClinicalTrials.gov